XTL Biopharmaceuticals Ltd. Sponsored ADR Stock

$2.70

0.00% day before yesterday

Nasdaq, Sep 06, 10:00 pm CET

ISIN

US98386D3070

Symbol

XTLB

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

XTL Biopharmaceuticals Ltd. Sponsored ADR Stock price

$2.70

+0.96 55.27% 5Y

Nasdaq, Closing price Fri, Sep 06 2024

+0.00 0.00%

ISIN

US98386D3070

Symbol

XTLB

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Market capitalization	$14.71m
Enterprise Value	$12.37m
P/E (TTM) P/E ratio	negative
P/B ratio (TTM) P/B ratio	5.44
Revenue (TTM) Revenue	$0.00
EBIT (operating result TTM) EBIT	$-689.00k
Cash position	$2.34m
EPS (TTM) EPS	$-0.07
Short interest	1.02%

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Get Started for Free Today

XTL Biopharmaceuticals Ltd. Sponsored ADR Stock Analysis

Unlock Scores for Free

??

1 Analyst has issued a forecast XTL Biopharmaceuticals Ltd. Sponsored ADR:

1x Buy

100%

More details on Analyst Estimates Including Price Targets

1 Analyst has issued a forecast XTL Biopharmaceuticals Ltd. Sponsored ADR:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from XTL Biopharmaceuticals Ltd. Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '24		+/- %
Revenue	- -	- 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	0.67 0.67	21% 21% -
- Research and Development Expense	0.02 0.02	50% 50% -
EBITDA	- -	- -
- Depreciation and Amortization	- -	- -
EBIT (Operating Income) EBIT	-0.69 -0.69	22% 22% -
Net Profit	-0.38 -0.38	86% 86% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

XTL Biopharmaceuticals Ltd. Sponsored ADR Stock News

Neutral

GlobeNewsWire

●

24 days ago

XTL Completed the Acquisition of The Social Proxy and a Private Placement of $1.5 Million

expands its IP portfolio to AI Web Data The Social Proxy is a web data AI company developing and powering an IP based platform for AI & BI Applications at scale Completed a Private Placement of $1.5 Million RAMAT GAN, ISRAEL, Aug. 14, 2024 (GLOBE NEWSWIRE) -- August 14, 2024, XTL Biopharmaceuticals Ltd. (the “Company” or “XTL”) announced today it has completed the acquisition of THE SOCIAL P...

Neutral

GlobeNewsWire

●

3 months ago

XTL Entered Definitive Agreement to Acquire The Social Proxy

expands its IP portfolio to AI Web Data The Social Proxy is a web data AI company developing and powering an IP based platform for AI & BI Applications at scale Secured $1.5 Million in a Private Placement RAMAT GAN, ISRAEL, June 05, 2024 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (the “Company” or “XTL”) announced today it has entered into a definitive share purchase agreement with the c...

Neutral

GlobeNewsWire

●

6 months ago

XTL To Aquire The Social Proxy

expands its IP portfolio to AI Web Data The Social Proxy is a web data AI company developing and powering an IP based platform for AI & BI Applications at scale Secured $1.5 Million in a Private Placement RAMAT GAN, ISRAEL, March 20, 2024 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (the “Company” or “XTL”) announced today that it has entered into a binding term sheet with THE SOCIAL PROXY ...

More XTL Biopharmaceuticals Ltd. Sponsored ADR News

Company Profile

XTL Biopharmaceuticals Ltd. focuses on the acquisition and development of proprietary products and late-stage pharmaceutical product candidates for the treatment of unmet clinical needs. The company was founded on March 9, 1993 and is headquartered in Raanana, Israel.

Head office	Israel
CEO	Shlomo Shalev
Employees	8
Founded	1993
Website	www.xtlbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now